Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity, Nature Reviews Cancer, vol.285, issue.2, pp.108-119, 2014. ,
DOI : 10.1038/nrc3648
Integrative Genetic Characterization and Phenotype Correlations in Pheochromocytoma and Paraganglioma Tumours, PLoS ONE, vol.23, issue.1, p.86756, 2014. ,
DOI : 10.1371/journal.pone.0086756.t004
Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas, Nature Communications, vol.26, p.6044, 2015. ,
DOI : 10.1038/ncomms7044
Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma, R111?122. Review about management and therapeutical options for patients with metastatic PPGL, 2013. ,
Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma, The American Journal of Human Genetics, vol.69, issue.1, pp.49-54, 2001. ,
DOI : 10.1086/321282
SDHA is a tumor suppressor gene causing paraganglioma, Human Molecular Genetics, vol.19, issue.15, pp.3011-3020, 2010. ,
DOI : 10.1093/hmg/ddq206
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901140
SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma, Science, vol.325, issue.5944, pp.1139-1142, 2009. ,
DOI : 10.1126/science.1175689
Mutations in SDHC cause autosomal dominant paraganglioma, type 3, Nat Genet, vol.26, pp.268-270, 2000. ,
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma, Nature Genetics, vol.24, issue.3, pp.229-233, 2010. ,
DOI : 10.1038/ng.533
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998199
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma, Nature Genetics, vol.8, issue.7, pp.663-667, 2011. ,
DOI : 10.1677/ERC-09-0016
Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene, JNCI Journal of the National Cancer Institute, vol.107, issue.5, 2015. ,
DOI : 10.1093/jnci/djv053
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas, PLoS Genet, vol.1, pp.72-80, 2005. ,
Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas, Molecular Endocrinology, vol.24, issue.12, pp.2382-2391, 2010. ,
DOI : 10.1210/me.2010-0256
Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma, Human Molecular Genetics, vol.20, issue.20, pp.3974-3985, 2011. ,
DOI : 10.1093/hmg/ddr324
URL : http://hmg.oxfordjournals.org/cgi/content/short/20/20/3974
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma, Cancer Cell, vol.23, issue.6, pp.739-752, 2013. ,
DOI : 10.1016/j.ccr.2013.04.018
Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways, Endocrine Related Cancer, vol.20, issue.4, pp.477-493, 2013. ,
DOI : 10.1530/ERC-12-0183
DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers, 3020?3030. DNA methylation study in metastatic PPGLs identifying prognostic markers, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2804
Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.10, pp.3822-3828, 2007. ,
DOI : 10.1210/jc.2007-0709
Mutations in the SDHB gene are associated with extra?adrenal and/or malignant phaeochromocytomas, Cancer Res, vol.63, pp.5615-5621, 2003. ,
SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes, Journal of Internal Medicine, vol.1073, issue.1, pp.19-42, 2009. ,
DOI : 10.1111/j.1365-2796.2009.02111.x
Gain-of-Function Mutations in Paraganglioma with Polycythemia, New England Journal of Medicine, vol.367, issue.10, pp.922-930, 2012. ,
DOI : 10.1056/NEJMoa1205119
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas, Human Molecular Genetics, vol.23, issue.9, pp.2440-2446, 2014. ,
DOI : 10.1093/hmg/ddt639
Germline FH mutations presenting with pheochromocytoma, J Clin Endocrinol Metab, vol.99, 2014. ,
Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis, Human Molecular Genetics, vol.22, issue.11, pp.2169-2176, 2013. ,
DOI : 10.1093/hmg/ddt069
Frequent EPAS1/HIF2alpha exons 9 and 12 mutations in non?familial pheochromocytoma, Endocr Relat Cancer, vol.21, 2014. ,
-Related Polycythemia-Paraganglioma Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.2, pp.369-373, 2014. ,
DOI : 10.1210/jc.2013-2600
URL : https://hal.archives-ouvertes.fr/inria-00607403
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma, 2711?2720. Demonstration that temozolomide is an effective treatment in SDHB?related malignant PPGLs, 2014. ,
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma, Human Molecular Genetics, vol.21, issue.26, pp.5397-5405, 2012. ,
DOI : 10.1093/hmg/dds374
Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas, Human Molecular Genetics, vol.21, issue.26, pp.5406-5416, 2012. ,
DOI : 10.1093/hmg/dds402
URL : http://hmg.oxfordjournals.org/cgi/content/short/21/26/5406
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, Thyroid, vol.25, issue.6, pp.567-610, 2015. ,
DOI : 10.1089/thy.2014.0335
Genetic Testing in Pheochromocytoma or Functional Paraganglioma, Journal of Clinical Oncology, vol.23, issue.34, pp.8812-8818, 2005. ,
DOI : 10.1200/JCO.2005.03.1484
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.6, 2014. ,
DOI : 10.1210/jc.2014-1498
MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma, Clinical Cancer Research, vol.18, issue.10, pp.2828-2837, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-0160
URL : https://hal.archives-ouvertes.fr/hal-01048691
in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.7, pp.1266-1271, 2013. ,
DOI : 10.1210/jc.2012-4257
Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis NGS analysis of 85 PPGL tumour samples for "mutation hotspots, Int J Endocrinol, vol.2015, p.138573, 2015. ,
Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients, sequencing?based genetic testing strategy in PPGLs, 2015. ,
DOI : 10.1136/jmedgenet-2015-103218
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas, Nature Communications, vol.206, p.6140, 2015. ,
DOI : 10.1038/ncomms7140
The genomic landscape of phaeochromocytoma, 78?89. Study of 40 PPGL tumour tissues using RNA?Seq , WES and SNP array, 2015. ,
DOI : 10.1002/path.4503
Whole?exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene, 542?554. Identification of KMT2D mutations in sporadic PPGLs using a WES strategy, 2015. ,
Absence of KMT2D/MLL2 mutations in abdominal paraganglioma, Clin Endocrinol (Oxf), 2015. ,
Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia, Prevalence of TERT promoter mutations in adrenal tumours and PGL, 2014. ,
DOI : 10.1530/ERC-13-0429
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors, Endocrine Related Cancer, vol.21, issue.3, pp.427-434, 2014. ,
DOI : 10.1530/ERC-14-0016
Universal Genetic Screening Uncovers a Novel Presentation of an SDHAF2 Mutation, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.7, pp.1392-1396, 2014. ,
DOI : 10.1210/jc.2013-4536
Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma, Endocrine Connections, vol.2, issue.2, pp.104-111, 2013. ,
DOI : 10.1530/EC-13-0009
A Comprehensive Next Generation Sequencing???Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.7, pp.1248-1256, 2013. ,
DOI : 10.1210/jc.2013-1319
Rare Germline Mutations Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and Paraganglioma, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.7, pp.1352-1360, 2014. ,
DOI : 10.1210/jc.2013-4375
Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes, Current Opinion in Endocrinology & Diabetes and Obesity, vol.22, issue.3, pp.169-179, 2015. ,
DOI : 10.1097/MED.0000000000000150
Spatio?temporal heterogeneity characterizes the genetic landscape of pheochromocytoma and defines early events in tumourigenesis Investigation of 136 PPGL tumour samples demonstrating a genetic heterogeneity between patients, between tumours of one patient and within tumour lesions, Clin Cancer Res FIGURE TITLE AND LEGEND, 2015. ,